FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB Number: Estimated average burden 0.5 hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	01 3601	1011 30(11) 01	the investment Company Act of 1	340				
Name and Address of Reporting Person* Lowery Thomas J. 2. Date of Event Requiring Statement (Month/Day/Year) 08/06/2014		ment	3. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [TTOO]					
(Last) (First) (Middle) 101 HARTWELL AVENUE	05/05/2011		Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner		(Mor	5. If Amendment, Date of Original Filed (Month/Day/Year)		
			 X Officer (give title below) 	Other (spe below)		dividual or Joint icable Line)	/Group Filing (Check	
(Street)			Chief Scientific (Officer	X	Form filed by	y One Reporting Person	
LEXINGTON MA 02421						Form filed by Reporting P	y More than One erson	
(City) (State) (Zip)								
7	Гable I - Noi	n-Deriva	tive Securities Beneficial	ly Owned				
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownersh Form: Direct or Indirect ((Instr. 5)	ct (D) (Instr. 5)		Beneficial Ownership	
Common Stock			5,882	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		d 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	n Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Stock Option	02/27/2013	02/27/2019	Common Stock	23,529	1.16	D		
Stock Option	02/05/2014	02/05/2020	Common Stock	20,588	1.31	D		
Stock Option	(1)	04/15/2023	Common Stock	29,411	1.96	D		
Stock Option	(2)	01/17/2022	2 Common Stock	38,235	2.45	D		
Stock Option	(3)	01/23/2023	Common Stock	11,764	2.25	D		
Stock Option	(4)	09/25/2023	3 Common Stock	59,102	3.22	D		
Stock Option	(5)	01/22/2024	4 Common Stock	16,602	3.22	D		
Stock Option	(6)	07/02/2024	Common Stock	26,564	10.7	D		

Explanation of Responses:

- 1. This Stock Option was granted on April 15, 2011 and vesting commenced on February 1, 2011. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.
- 2. This Stock Option was granted on January 17, 2012 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting $commencement\ date\ and\ options\ to\ purchase\ the\ remaining\ shares\ vest\ in\ 36\ equal\ monthly\ installments\ thereafter.$
- 3. This Stock Option was granted on January 23, 2013 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter. 4. This Stock Option was granted on September 25, 2013 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting
- commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.
- 5. This Stock Option was granted on January 22, 2014 and vesting commenced on the grant date. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.
- 6. This Stock Option was granted on July 2, 2014 and vesting commenced on June 25, 2014. Options to purchase 25% of the total underlying shares vest on the first anniversary of the vesting commencement date and options to purchase the remaining shares vest in 36 equal monthly installments thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Thomas J. Lowery, Ph.D.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of (i) the Chief Financial Officer of T2 Biosystems, Inc., a Delaware corporation (the "Company"), who is currently Marc R. Jones, and (ii) the Company's Comptroller, who is currently Christopher Martin, and their respective successors, signing singly, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 and any amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of August, 2014.

Signature: /s/ Thomas J. Lowery

Name: Thomas J. Lowery